These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 35600852)

  • 1. Corrigendum: Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta
    Cui Y; Cui D; Ren X; Chen X; Liu G; Liu Z; Wang Y; Qu X; Zhao Y; Yang H
    Front Pharmacol; 2022; 13():907413. PubMed ID: 35600852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta® in Healthy Chinese Male Volunteers.
    Cui Y; Cui D; Ren X; Chen X; Liu G; Liu Z; Wang Y; Qu X; Zhao Y; Yang H
    Front Pharmacol; 2021; 12():660541. PubMed ID: 34149414
    [No Abstract]   [Full Text] [Related]  

  • 3. A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjects.
    Liu G; Xu Z; Yang W; Xue J; Wang Y; Liu Z; Cui Y; Qu X; Chang T; Yu S; Cheng Y; Zhou Y; Chen J; Ren Q; Wang W; Deng Q; Wang Z; Yang H
    Expert Opin Biol Ther; 2022 Feb; 22(2):187-195. PubMed ID: 34607519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrigendum: Pharmacokinetics and bioequivalence study of esomeprazole magnesium enteric-coated tablets 20 mg in healthy Chinese subjects under fasting and fed conditions.
    Ding Y; Chu N; Que L; Huang K; Chen Y; Qin W; Qian Z; Shi Y; Xu Z; He Q
    Front Pharmacol; 2023; 14():1217008. PubMed ID: 37324482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, single-dose, two-way, parallel phase I clinical study comparing the pharmacokinetics and safety of adalimumab injecta and Humira® in healthy Chinese male volunteers.
    Wang Y; Gao Z; Liu Z; Liu G; Qu X; Chen J; Ren X; Xu Z; Yang H
    Expert Opin Biol Ther; 2022 Feb; 22(2):225-234. PubMed ID: 34134579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The similarity of pharmacokinetics, pharmacodynamics, safety, and immunogenicity between recombinant fully human anti-RANKL monoclonal antibody injection (MW032) and denosumab (Xgeva®) in healthy Chinese subjects: A single-center, randomized, double-blind, single-dose, parallel-controlled clinical study.
    Hou J; Hu Z; Xu W; Di Y; Song C; Wu F; Liu J; Guo Y
    Int Immunopharmacol; 2022 Jun; 107():108666. PubMed ID: 35286913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corrigendum: Population Pharmacokinetic/Pharmacodynamic Model-Guided Dosing Optimization of a Novel Sedative HR7056 in Chinese Healthy Subjects.
    Zhou Y; Hu P; Huang Y; Sang N; Song K; Wang H; Wen J; Jiang J; Chen X
    Front Pharmacol; 2019; 10():251. PubMed ID: 30941039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product Avastin® in healthy Chinese male subjects.
    Zhou R; Yang J; Liu Y; Zhang Q; Lu C; Tang K; Li X; Tang W; Gao E; Wu C; Dou C; Hu W
    Expert Opin Biol Ther; 2022 Feb; 22(2):263-269. PubMed ID: 34913787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of pharmacokinetics and safety with bioequivalence of Amlodipine in healthy Chinese volunteers: Bioequivalence Study Findings.
    Wang T; Wang Y; Lin S; Fang L; Lou S; Zhao D; Zhu J; Yang Q; Wang Y
    J Clin Lab Anal; 2020 Jun; 34(6):e23228. PubMed ID: 32034814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic bioequivalence, safety, and immunogenicity of GB222, a bevacizumab biosimilar candidate, and bevacizumab in Chinese healthy males: a randomized clinical trial.
    Dong W; Chen M; Niu S; Wang B; Xia L; Wang J; Shen T; Wang Q; Lv J; Liu G; Fan H; Xie Z; Xie F; An Y; Zheng Q; Rao H; Song H; Fang Y
    Expert Opin Biol Ther; 2022 Feb; 22(2):253-262. PubMed ID: 34236011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corrigendum: Tengdan Capsule Prevents Hypertensive Kidney Damage in SHR by Inhibiting Periostin-Mediated Renal Fibrosis.
    Du X; Tao Q; Du H; Zhao Z; Dong Y; He S; Shao R; Wang Y; Han W; Wang X; Zhu Y
    Front Pharmacol; 2021; 12():814501. PubMed ID: 35173612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrigendum: Integrated network pharmacology and metabolomics to reveal the mechanism of QiShenYiQi Dripping Pills against cardiac structural and functional abnormalities.
    Zhang J; Yang Z; Jia X; Li X; Wang X; Rong H; Liang Y; Zeng W; Jia W; Ma X
    Front Pharmacol; 2022; 13():1080645. PubMed ID: 36479197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corrigendum: The Efficacy and Safety of Qiming Granule for Dry Eye Disease: A Systematic Review and Meta-Analysis.
    Yang M; Hu Z; Yue R; Yang L; Zhang B; Chen Y
    Front Pharmacol; 2020; 11():597639. PubMed ID: 33362551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized Phase I pharmacokinetic trial comparing the potential biosimilar trastuzumab (SIBP-01) with the reference product (Herceptin®) in healthy Chinese male volunteers.
    Zhou H; Cao S; Zhu X; Xie J; Fan L; Ge Q; Wang Y; Zhu J; Liu Y; Shao Z; Shan R; Liu B; Wang H; Ding L
    Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):997-1003. PubMed ID: 32847423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corrigendum: Efficacy and Safety of Shenqu Xiaoshi Oral Liquid Compared With Domperidone Syrup in Children With Functional Dyspepsia.
    Yu Y; Xie XL; Wu J; Li ZY; He ZG; Liang CJ; Jin ZQ; Wang AZ; Gu J; Huang Y; Mei H; Shi W; Hu SY; Jiang X; Du J; Hu CJ; Gu L; Jiang ML; Mao ZQ; Xu CD
    Front Pharmacol; 2022; 13():920925. PubMed ID: 35770095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects.
    Chen H; Chen W; Yuan F; Guo Q; Zhang X; Wang C; Li X
    Front Pharmacol; 2022; 13():821944. PubMed ID: 35140619
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase I, randomized, double-blind, single-dose study to assess the pharmacokinetics, safety, and immunogenicity of the proposed biosimilar SCT630 and adalimumab in healthy Chinese subjects.
    Liu L; Qi L; Lei C; Wang Y; Zhang W; Liu Y; Li P; Bai H; Li Y; Li Y; Liu J; Xie L; Wang X
    Int Immunopharmacol; 2022 May; 106():108599. PubMed ID: 35193054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized, Double-Blind, Single-Dose Study Comparing the Biosimilarity of HOT-1010 With Bevacizumab (Avastin®) in Chinese Healthy Male Subjects.
    Huang K; Que L; Ding Y; Chu N; Qian Z; Shi Y; Qin W; Li Z; Chen Y; Gu X; Wang J; Zhang L; Zhang J; Zhu X; Yang Y; Tang Y; He Q
    Front Pharmacol; 2021; 12():694375. PubMed ID: 34220519
    [No Abstract]   [Full Text] [Related]  

  • 19. A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers.
    Wang J; Qi L; Liu L; Wang Z; Chen G; Wang Y; Liu X; Liu Y; Liu H; Tong Y; Liu C; Lei C; Wang X
    Front Pharmacol; 2019; 10():905. PubMed ID: 31474863
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum: Potential Mechanisms of Action of Chinese Patent Medicines for COVID-19: A Review.
    Yang ZH; Wang B; Ma Q; Wang L; Lin YX; Yan HF; Fan ZX; Chen HJ; Ge Z; Zhu F; Wang HJ; Zhang BN; Sun HD; Feng LM
    Front Pharmacol; 2021; 12():770125. PubMed ID: 34759829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.